| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2002 ( Subtotal = $606,246 ) |
| | 2002 | 2002 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA085130 | PRETARGETED RIT TO TREAT NON-HODGKIN'S LYMPHOMA | 000 | 3 | NIH | 1/31/2002 | $358,187 |
| | 2002 | 2002 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R42CA085106 | MELANOMA THERAPY VIA PEPTIDE TARGETED ALPHA-RADIATION | 000 | 2 | NIH | 9/30/2002 | $248,059 |
|
| Issue Date FY: 2001 ( Subtotal = $1,148,436 ) |
| | 2001 | 2001 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA085130 | PRETARGETED RIT TO TREAT NON-HODGKIN'S LYMPHOMA | 000 | 2 | NIH | 1/15/2001 | $725,196 |
| | 2001 | 2001 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA071221 | ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212 | 000 | 5 | NIH | 4/16/2001 | $314,561 |
| | 2001 | 2001 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R43CA090159 | GEMCITABINE POTENTIATION OF PRETARGET RIT | 000 | 1 | NIH | 6/22/2001 | $108,679 |
|
| Issue Date FY: 2000 ( Subtotal = $421,780 ) |
| | 2000 | 2000 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R41CA085106 | MELANOMA RADIOTHERAPY- PEPTIDE TARGETED ALPHA-RADIATION | 000 | 1 | NIH | 1/31/2000 | $100,033 |
| | 2000 | 2000 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | FDR001660 | HO-166 DOTMP FOR TREATMENT OF MULTIPLE MYELOMA | 00 | 02 | FDA | 9/26/2000 | $205,009 |
| | 2000 | 2000 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA085130 | PRETARGETED RIT TO TREAT NON-HODGKIN'S LYMPHOMA | 000 | 1 | NIH | 12/27/1999 | $104,167 |
| | 2000 | 2000 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA071221 | ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212 | 000 | 4 | NIH | 5/19/2000 | $12,571 |
| | 2000 | 1999 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | FDR001660 | HO-166 DOTMP FOR TREATMENT OF MULTIPLE MYELOMA | 03 | 01 | FDA | 2/15/2000 | $0 |
| | 2000 | 1999 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | FDR001660 | HO-166 DOTMP FOR TREATMENT OF MULTIPLE MYELOMA | 01 | 01 | FDA | 11/8/1999 | $0 |
| | 2000 | 1999 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | FDR001660 | HO-166 DOTMP FOR TREATMENT OF MULTIPLE MYELOMA | 02 | 01 | FDA | 12/16/1999 | $0 |
|
| Issue Date FY: 1999 ( Subtotal = $156,589 ) |
| | 1999 | 1999 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | FD-R-001660 | HO-166 DOTMP FOR TREATMENT OF MULTIPLE MYELOMA | 0 | 01 | FDA | 9/27/1999 | $109,874 |
| | 1999 | 1999 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA071221 | ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212 | 001 | 2 | NIH | 5/28/1999 | $634 |
| | 1999 | 1999 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA071221 | ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212 | 000 | 3 | NIH | 5/31/1999 | $46,081 |
|
| Issue Date FY: 1998 ( Subtotal = $378,164 ) |
| | 1998 | 1998 | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R44CA071221 | ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212 | 000 | 2 | NIH | 4/17/1998 | $378,164 |
|
| Issue Date FY: 1997 ( Subtotal = $195,839 ) |
| | 1997 | | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R43HL59084 | COLD STORAGE OF PLATELETS | 000 | 01 | NIH | 9/29/1997 | $95,839 |
| | 1997 | | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R43CA71221 | ALPHA RADIOTHERAPY VIA PRETARGETED LEAD 212 | 000 | 01 | NIH | 1/28/1997 | $100,000 |
|
| Issue Date FY: 1996 ( Subtotal = $99,046 ) |
| | 1996 | | NEORX CORPORATION | 410 WEST HARRISON STREET | SEATTLE | WA | 98119 | KING | USA | R41HL57036 | IMPROVED ANNEXIN V DERIVATIVES FOR THROMBUS IMAGING | 000 | 01 | NIH | 9/30/1996 | $99,046 |
|
|
